Making a difference with your help.
Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Sponsor: Boehringer Ingelheim Indication: CKD GFR: 20-90 DETAILS >
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 to ≤75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Safety and efficacy of BAY 3283142 in patients with chronic kidney disease Sponsor: Bayer Indication: CKD & HTN GFR: ≥20 and ≤75 DETAILS >
Safety and efficacy of BAY 3283142 in patients with chronic kidney disease Read More »
Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity GFR: 21-75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Observational Study Protocol – Fabry Disease Registry Sponsor: Sanofi-Aventis Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study Protocol – Fabry Disease Registry Read More »
Protocol Name: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease Primary Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >